Deficient SARS-CoV-2 hybrid immunity during inflammatory bowel disease

Patients with Inflammatory Bowel Disease (IBD) undergoing immunosuppressive therapies face heightened susceptibility to severe COVID-19. An in-depth understanding of systemic inflammation and cellular immune responses after SARS-CoV-2 vaccination and breakthrough infections (BTI) is required for opt...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Clinical immunology (Orlando, Fla.) Fla.), 2024-12, Vol.271, p.110404
Hauptverfasser:	Alirezaylavasani, Amin, Egner, Ingrid Marie, Dahl, Børresdatter, Chopra, Adity, de Matos Kasahara, Taissa, Goll, Guro Løvik, Jahnsen, Jørgen, Grødeland, Gunnveig, Vaage, John Torgils, Lund-Johansen, Fridtjof, Holter, Jan Cato, Halvorsen, Bente, Jørgensen, Kristin Kaasen, Munthe, Ludvig A, Kared, Hassen
Format:	Artikel
Sprache:	eng
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!